Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
Will Immunotherapy Shift the Balance of Treatment for Borderline Resectable Stage III NSCLC Away from Surgery? (BMIC-014)
